News
Kingsview Wealth Management recently bought a new stake in Vertex Pharmaceuticals. They snagged 545 shares, valued around ...
For the third summer in a row, Vertex Pharmaceuticals brought its commitment to community and STEM education to life through ...
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...
Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...
Vertex Pharmaceuticals, under the leadership of CEO Reshma Kewalramani, was named in the “Impact Awards” category, which spotlights five standout companies making meaningful advancements in their ...
Vertex Pharmaceuticals has solidified its leadership in the cystic fibrosis (CF) market through strategic innovation and ...
Explore more
Vertex Pharmaceuticals' new therapy, zimislecel, has potential to be a "functional cure," experts say. A new stem cell ...
Valued at a market cap of $117.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company that ...
Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...
NRI PULSE STAFF REPORT The 2025 edition of TIME100 Most Influential Companies honors leaders and innovators who are ...
Key Points Alibaba is a Chinese AI stock that's dirt cheap. Meta Platforms is making a huge bet on AI that should pay off ...
Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 10 years ago, it would be worth $3,509.46 today based on a price of $459.81 for VRTX at the time of writing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results